Artificial intelligence in drug discovery: current trend, challenges and future perspectives
Year: 2026
Type: article
Abstract: Artificial intelligence (AI) is transforming the field of drug discovery by improving the speed, efficiency, and accuracy of the development process. Conventional drug discovery is time-consuming, expensive, and associated with a high rate of clinical failure. AI-based approaches, including machine learning (ML), deep learning (DL), natural language processing (NLP), and reinforcement learning (RL), enable researchers to analyze large biological and chemical datasets, identify potential therapeutic targets, and design new molecules with desired properties. These technologies are widely applied in target identification, virtual screening, lead optimization, toxicity prediction, and clinical trial planning. AI also supports precision medicine by integrating genomic, proteomic, and clinical data to guide personalized treatment strategies. Several AI-designed drug candidates have already entered clinical evaluation, highlighting the practical impact of these methods. Despite these advances, important challenges remain, including limitations in data quality, model interpretability, reproducibility, regulatory acceptance, and ethical concerns such as privacy and algorithmic bias. Emerging developments in explainable AI, federated learning, multi-omics integration, and hybrid computational models are expected to further enhance the reliability and applicability of AI-driven drug discovery. This review summarizes current applications of AI in pharmaceutical research, discusses major challenges, and outlines future directions for the development of safer, faster, and more cost-effective therapeutics.
Authors: Sharanjit Kaur, Tanvi Sawhney, Sanjiv Duggal
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W7162668940
